Curi RMB Capital
ECYT

Curi RMB Capital’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Curi RMB Capital’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-249,885
Closed -$4.44M – 1033
2018
Q3 		$4.44M Sell
249,885
-15,000
-6% -$258K 0.11% 225
2018
Q2 		$3.65M Hold
264,885
– – 0.09% 253
2018
Q1 		$2.41M Hold
264,885
– – 0.06% 353
2017
Q4 		$1.13M Hold
264,885
– – 0.03% 465
2017
Q3 		$373K Hold
264,885
– – 0.01% 566
2017
Q2 		$397K Hold
264,885
– – 0.01% 564
2017
Q1 		$681K Buy
264,885
+21,500
+9% +$49.7K 0.03% 337
2016
Q4 		$621K Buy
243,385
+25,500
+12% +$73.2K 0.03% 285
2016
Q3 		$673K Hold
217,885
– – 0.04% 282
2016
Q2 		$699K Hold
217,885
– – 0.04% 271
2016
Q1 		$675K Buy
217,885
+400
+0.2% +$1.31K 0.04% 249
2015
Q4 		$872K Hold
217,485
– – 0.04% 251
2015
Q3 		$996K Sell
217,485
-2,715
-1% -$14.2K 0.07% 265
2015
Q2 		$1.14M Hold
220,200
– – 0.07% 227
2015
Q1 		$1.38M Buy
220,200
+1,000
+0.5% +$5.77K 0.08% 234
2014
Q4 		$1.38M Sell
219,200
-100
-0% -$610 0.08% 238
2014
Q3 		$1.33M Buy
219,300
+25,100
+13% +$171K 0.08% 245
2014
Q2 		$1.28M Buy
194,200
+15,000
+8% +$169K 0.08% 238
2014
Q1 		$4.27M Sell
179,200
-45,575
-20% -$661K 0.29% 80
2013
Q4 		$2.4M Buy
224,775
+575
+0.3% +$6.35K 0.17% 140
2013
Q3 		$2.99M Buy
224,200
+3,200
+1% +$50.6K 0.21% 115
2013
Q2 		$2.9M Buy
+221,000
New +$2.98M 0.22% 108

Other funds holding ECYT

OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
CA
Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Curi RMB Capital's ECYT Position: Q4 2018 in Review

Curi RMB Capital sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 249,885 shares — an estimated $4.44M sold.

Curi RMB Capital first reported a position in ECYT in Q2 2013 and held it in 22 quarters. The position peaked at $4.44M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

  • Curi RMB Capital reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Curi RMB Capital sold 249,885 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $4.44M.
  • Curi RMB Capital first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 22 quarters.
  • Curi RMB Capital's Endocyte, Inc. Common Stock position peaked at $4.44M in Q3 2018.
  • 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Curi RMB Capital's 13F filing for Q4 2018, filed 13 Feb 2019.